Aimmune’s ‘First-Of-Its-Kind’ Peanut Allergy Drug Receives FDA Approval

The FDA approved Palforzia allergen powder for treating patients with confirmed diagnosis of peanut allergy, the Brisbane, California-based company said in a late Friday release. An FDA panel, which reviewed the BLA for Palforzia back in September, voted 7-2, recommending the approval on the grounds of efficacy and safety. Palforzia is an oral immunotherapy meant to mitigate allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. …read more

Source:: Yahoo Finance

Discover Tomorrow’s Winning Stocks!
Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.